Trials / Completed
CompletedNCT02962440
A Trial Investigating the Absorption, Metabolism and Excretion of Somapacitan After Single Dosing in Healthy Male Subjects
A Single Centre, Open Label Trial Investigating the Absorption, Metabolism and Excretion of Somapacitan After Single Subcutaneous Dosing in Healthy Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- Male
- Age
- 45 Years – 64 Years
- Healthy volunteers
- Accepted
Summary
This trial is conducted in Europe. The aim of the trial is to investigate the absorption, metabolism and excretion of somapacitan after single subcutaneous dosing in healthy male subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | somapacitan | All subjects will receive one subcutaneous (s.c., under the skin) dose of somapacitan containing \[3H\]-somapacitan |
Timeline
- Start date
- 2016-11-01
- Primary completion
- 2017-01-01
- Completion
- 2017-01-01
- First posted
- 2016-11-11
- Last updated
- 2017-06-07
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT02962440. Inclusion in this directory is not an endorsement.